Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clinical Trial Enrollment

- PMLiVE

Behavioural science – the route to healthcare salvation?

Industry is urged to ditch the simple slogans and instead embrace the complexity, as delving more deeply could improve success rates

- PMLiVE

The PM Society – giving back

Highlighting some of the initiatives, donations and work streams that the organisation has led

- PMLiVE

Effective Communication in Virtual Meetings: Stay Pithy – Impetus InSite Tips #4

Learn the value of concise communication in our fourth tip for optimizing virtual meetings. Discover how keeping interactions short and focused can drastically improve engagement and retention in today's fast-paced...

Impetus Digital

- PMLiVE

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn

The selected candidate can be developed as a monotherapy, combination therapy or both

- PMLiVE

Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS

The chronic neurological condition affects more than 2.8 million people worldwide

- PMLiVE

Novartis presents positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

- PMLiVE

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

CKD is a progressive condition that affects nearly 850 million people worldwide

- PMLiVE

Women’s health – managing the menopause

PME spoke to Marci English, Vice President and Head of BioPharma Development, Astellas, about the importance of new treatments for menopause symptoms, the unmet need and the company’s commitment to...

- PMLiVE

Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050

- PMLiVE

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links